E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers O > Headlines for Orthologic Corp. > News item
Published on 3/7/2006 in the Prospect News Biotech Daily.

OrthoLogic moves release date of top-line results from phase 3 Chrysalin trial

By Lisa Kerner

Erie, Pa., March 7 - OrthoLogic Corp. announced revised guidance for the expected release of top-line results from its phase 3 clinical trial of the novel synthetic peptide Chrysalin (TP508) in fracture repair.

Results are expected to be released by March 31 instead of the previously provided guidance of April 30.

OrthoLogic is a biotechnology company based in Tempe, Ariz.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.